These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 24970798)
41. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. Luo BH; Xiong F; Wang JP; Li JH; Zhong M; Liu QL; Luo GQ; Yang XJ; Xiao N; Xie B; Xiao H; Liu RJ; Dong CS; Wang KS; Wen JF PLoS One; 2014; 9(6):e99922. PubMed ID: 24945379 [TBL] [Abstract][Full Text] [Related]
42. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Connolly E; Braunstein S; Formenti S; Schneider RJ Mol Cell Biol; 2006 May; 26(10):3955-65. PubMed ID: 16648488 [TBL] [Abstract][Full Text] [Related]
43. Eukaryotic Initiation Factor 4E phosphorylation acts a switch for its binding to 4E-BP1 and mRNA cap assembly. Batool A; Majeed ST; Aashaq S; Majeed R; Andrabi KI Biochem Biophys Res Commun; 2020 Jun; 527(2):489-495. PubMed ID: 32336547 [TBL] [Abstract][Full Text] [Related]
44. Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells. Guan L; Song K; Pysz MA; Curry KJ; Hizli AA; Danielpour D; Black AR; Black JD J Biol Chem; 2007 May; 282(19):14213-25. PubMed ID: 17360714 [TBL] [Abstract][Full Text] [Related]
45. Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1. Willett M; Cowan JL; Vlasak M; Coldwell MJ; Morley SJ Cell Signal; 2009 Oct; 21(10):1504-12. PubMed ID: 19481146 [TBL] [Abstract][Full Text] [Related]
46. Activation of p53 stimulates proteasome-dependent truncation of eIF4E-binding protein 1 (4E-BP1). Constantinou C; Elia A; Clemens MJ Biol Cell; 2008 May; 100(5):279-89. PubMed ID: 18021075 [TBL] [Abstract][Full Text] [Related]
47. Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3. Tsukumo Y; Alain T; Fonseca BD; Nadon R; Sonenberg N Nat Commun; 2016 Jun; 7():11776. PubMed ID: 27319316 [TBL] [Abstract][Full Text] [Related]
48. Activation of the translational suppressor 4E-BP1 following infection with encephalomyocarditis virus and poliovirus. Gingras AC; Svitkin Y; Belsham GJ; Pause A; Sonenberg N Proc Natl Acad Sci U S A; 1996 May; 93(11):5578-83. PubMed ID: 8643618 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail. Lu L; Chen Z; Lin X; Tian L; Su Q; An P; Li W; Wu Y; Du J; Shan H; Chiang CM; Wang H Cell Death Differ; 2020 Jan; 27(1):255-268. PubMed ID: 31114028 [TBL] [Abstract][Full Text] [Related]
51. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128 [TBL] [Abstract][Full Text] [Related]
52. Translational repression of Ccl5 and Cxcl10 by 4E-BP1 and 4E-BP2 restrains the ability of mouse macrophages to induce migration of activated T cells. William M; Leroux LP; Chaparro V; Graber TE; Alain T; Jaramillo M Eur J Immunol; 2019 Aug; 49(8):1200-1212. PubMed ID: 31032899 [TBL] [Abstract][Full Text] [Related]
53. Contribution of HIF-1α in 4E-BP1 gene expression. Azar R; Lasfargues C; Bousquet C; Pyronnet S Mol Cancer Res; 2013 Jan; 11(1):54-61. PubMed ID: 23175522 [TBL] [Abstract][Full Text] [Related]
54. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. Haghighat A; Mader S; Pause A; Sonenberg N EMBO J; 1995 Nov; 14(22):5701-9. PubMed ID: 8521827 [TBL] [Abstract][Full Text] [Related]
55. RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Shull AY; Noonepalle SK; Awan FT; Liu J; Pei L; Bollag RJ; Salman H; Ding Z; Shi H Oncotarget; 2015 Jun; 6(16):14632-45. PubMed ID: 25999352 [TBL] [Abstract][Full Text] [Related]
56. CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability. Choi SH; Martinez TF; Kim S; Donaldson C; Shokhirev MN; Saghatelian A; Jones KA Genes Dev; 2019 Apr; 33(7-8):418-435. PubMed ID: 30819820 [TBL] [Abstract][Full Text] [Related]
57. Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells. Ochnik AM; Peterson MS; Avdulov SV; Oh AS; Bitterman PB; Yee D Neoplasia; 2016 Feb; 18(2):100-10. PubMed ID: 26936396 [TBL] [Abstract][Full Text] [Related]
58. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Dodd KM; Yang J; Shen MH; Sampson JR; Tee AR Oncogene; 2015 Apr; 34(17):2239-50. PubMed ID: 24931163 [TBL] [Abstract][Full Text] [Related]
59. Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer. Lv T; Wang Q; Cromie M; Liu H; Tang S; Song Y; Gao W Oncotarget; 2015 Oct; 6(32):33006-18. PubMed ID: 26360779 [TBL] [Abstract][Full Text] [Related]
60. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]